Clinical Trial Design Considerations in Assessing Long‐Term Functional Impacts of Tiotropium in COPD: The Uplift Trial

References

• Mannino D M, Homa D M, Akinbami L J, Ford E S, Redd S C. Chronic obstructive pulmonary disease surveillance—United States, 1971–2000. Surveillance Summaries, August 2, 2002. MMWR, 2002; Vol. 51: 1–16
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. National Heart Lung and Blood Institute, Bethesda April, 2001, Update of the management sections, GOLD website (www.goldcopd.com), update July 2003
   Google Scholar
• Tashkin D P, Detels R, Simmons M, Liu H, Coulson A H, Sayre J, Rokaw S. The UCLA population studies of chronic obstructive respiratory disease: XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am J Respir Crit Care Med 1994; 149: 1209–1217, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lange P, Groth S, Nyboe G J, Mortensen J, Appleyard M, Jensen G, Schnohr P. Effects of smoking and changes in smoking habits on the decline of FEV1. Eur Respir J 1989; 2: 811–816, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Xu X, Weiss S T, Rijcken B, Schouten J P. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur Respir J 1994; 7: 1056–1061, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Connett J E, Kiley J P, Altose M D, Bailey W C, Buist A S, Conway W A, Jr, Enright P L, Kanner R E, O'Hara P, Owens G R, Scanlon P D, Tashkin D P, Wise for the Lung Health Study Group R A. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1, the Lung Health Study. JAMA 1994; 272: 1497–1505, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kanner R E, Anthonisen N R, Connett J E, for the Lung Health Study Research Group. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex‐smokers with mild chronic obstructive pulmonary disease, results from the Lung Health Study. Am J Respir Crit Care Med 2000; 164: 358–364, [CSA]
   Web of Science ®Google Scholar
• Traver G A, Cline M G, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease—a 15 year follow‐up study. Am Rev Respir Dis 1979; 119: 895–902, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley P MA, Burge P S, Jones on behalf of the ISOLDE Study Group P W. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122–128, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Witek T J, Mahler D A. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56: 248–255, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Garcia‐Aymerich J, Monso E, Marrades R M, Escarrabill J, Felez M A, Sunyer J, Anto and the EFRAM Investigators J M. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbations, EFRAM study. Am J Respir Crit Care Med 2001; 164: 1002–1007, [CSA]
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standardization of spirometry—1994 update. Am J Respir Crit Care Med 1995; 152: 1107–1136, [CSA]
   PubMed Web of Science ®Google Scholar
• Disse B, Speck G A, Rominger K L, Witek T J, Jr, Hammer R. Tiotropium (Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64: 457–464, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler D A, Jones P A, Wanner A, San Pedro G, ZuWallack R L, Menjoge S S, Serby C W, Witek T J. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–224, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord J A, Greefhorst A PM, Bantje Th A, Kesten S, Korducki L, Cornielissen P JG. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19: 209–216, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Anzueto A, Menjoge S S, Kesten S. Changes in FEV1 overtime in one year clinical trials of tiotropium in COPD. Am J Respir Crit Care Med 2001; 163: A280
   PubMedGoogle Scholar
• O'Donnell D, Fluge T, Gerken F, Hamilton A, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPD. Eur Respir J 2004, In press
   Google Scholar
• Connett J E, Kusek J W, Bailey W C, O'Hara P, Wu M. Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. Control Clin Trials 1993; 14: 3S–19S, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1995; 152: 77–120
   PubMed Web of Science ®Google Scholar
• Quanjer P H. Standardised lung function testing of the European community for coal and steel. Bull Euro Physiopathol Respir 1983; 19: 7–28
   PubMedGoogle Scholar
• Jones P W, Quirk F H, Baveystock C M, Littlejohns P. A self‐complete measure of health status for chronic airflow limitation: the St. George's respiratory questionnaire. Am Rev Respir Dis 1992; 145: 1321–1327, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Laid N M, Ware J H. Random‐effects models for longitudinal data. Biometrics 1982; 38: 963–974
   PubMed Web of Science ®Google Scholar
• Burge P S, Calverley P MA, Jones P W, Spencer S, Anderson J A, Maslen on behalf of the ISOLDE study investigators T K. Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–1303, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Lofdahl C G, Laitinen L A, Schouten J P, Postma D S, Pride N B, Ohlsson S V, for the European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking, European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948–1953, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902–1909, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391–398
   PubMed Web of Science ®Google Scholar
• Donaldson G C, Seemungal T AR, Bhowmik A, Wedzicha J A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Domingo‐Salveny A, Lamarca R, Ferrer M, Garcia‐Aymerich J, Alonso J, Fekez M, Khalaf A, Marrades R M, Monso E, Sera‐Batlles J, Anto J. Health‐related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 680–685, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia J L, Garau J. Mortality after hospitalization for COPD. Chest 2002; 121: 1441–1448, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rand C S, Wise R A, Nides M, Simmons M S, Bleecker E R, Kusch J W, Li V C, Tashkin D P. Inhaler adherence in a clinical trial: comparison of self‐report and canister weighing to the nebulizer chronolog. Am Rev Respir Dis 1992; 146: 1550–1564
   Google Scholar
• Sutherland E R, Allmers H, Ayas N T, Venn A J, Martin R J. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta‐analysis. Thorax 2003; 58: 937–941, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Highland K B, Strange C, Heffner J E. Long‐term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. Ann Intern Med 2003; 138: 969–973, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Enright P L, Hohnson L R, Connett J E, Voelker H, Buist A S. Spirometry in the Lung Health Study, methods and quality control. Am Rev Respir Dis 1991; 143: 1215–1223, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Calverley P MA, Lee A, Towse L, van Noord J, Witek T J, Kesten S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58: 855–860, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden for the TRISTAN Study Group C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Little R JA, Rubin D B. Statistical Analysis with Missing Data. Wiley, New York 1987
   Google Scholar
• Shumaker S A, Dugan E, Bowen D J. Enhancing adherence in randomized contolled clinical trials. Control Clin Trials 2000; 21: 226–232, [CROSSREF]
   Google Scholar